Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARTL NASDAQ:ENSC OTCMKTS:GLUC NASDAQ:KTTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTLArtelo Biosciences$9.25+2.3%$11.92$4.92▼$28.60$6.52M1.4678,833 shs13,417 shsENSCEnsysce Biosciences$2.09-0.5%$2.15$1.62▼$14.67$6.20M1114,672 shs25,416 shsGLUCGlucose Health$0.09+2.3%$0.10$0.08▼$0.28$1.64M1.765,559 shs9,318 shsKTTAPasithea Therapeutics$0.81-3.9%$0.72$0.65▼$7.50$6.02M0.28132,301 shs296,277 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTLArtelo Biosciences0.00%-2.22%-9.31%+45.58%+18.59%ENSCEnsysce Biosciences0.00%+1.95%+1.95%-9.13%-64.73%GLUCGlucose Health0.00%+3.41%-11.23%+3.86%-62.36%KTTAPasithea Therapeutics0.00%+13.83%+15.75%-12.15%-82.24%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARTLArtelo Biosciences3.1537 of 5 stars3.85.00.00.03.20.00.6ENSCEnsysce Biosciences1.0129 of 5 stars0.04.00.00.03.80.00.6GLUCGlucose HealthN/AN/AN/AN/AN/AN/AN/AN/AKTTAPasithea Therapeutics1.1187 of 5 stars0.05.00.00.03.10.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARTLArtelo Biosciences 3.60Strong Buy$24.00159.46% UpsideENSCEnsysce Biosciences 0.00N/AN/AN/AGLUCGlucose Health 0.00N/AN/AN/AKTTAPasithea Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest GLUC, ARTL, KTTA, and ENSC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/26/2025ARTLArtelo BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.008/18/2025ARTLArtelo BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.008/4/2025ARTLArtelo BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$20.00 ➝ $18.007/8/2025ARTLArtelo BiosciencesD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy7/8/2025ARTLArtelo BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$20.006/11/2025ARTLArtelo BiosciencesD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/6/2025ARTLArtelo BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARTLArtelo BiosciencesN/AN/AN/AN/A$5.31 per shareN/AENSCEnsysce Biosciences$5.21M1.19N/AN/A$2.59 per share0.81GLUCGlucose Health$380K4.31N/AN/AN/A∞KTTAPasithea TherapeuticsN/AN/AN/AN/A$10.60 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARTLArtelo Biosciences-$9.83M-$19.05N/AN/AN/AN/A-497.68%-213.76%11/10/2025 (Estimated)ENSCEnsysce Biosciences-$7.99M-$4.03N/AN/AN/A-88.76%-167.23%-104.59%11/11/2025 (Estimated)GLUCGlucose Health-$320K-$0.03N/A∞N/A-82.29%N/AN/AN/AKTTAPasithea Therapeutics-$13.90M-$7.55N/A∞N/AN/A-88.60%-81.10%11/11/2025 (Estimated)Latest GLUC, ARTL, KTTA, and ENSC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025KTTAPasithea TherapeuticsN/A-$0.66N/A-$0.66N/AN/A8/13/2025Q2 2025ARTLArtelo Biosciences-$0.13-$5.61-$5.48-$5.61N/AN/A8/13/2025Q2 2025ENSCEnsysce Biosciences-$1.02-$0.79+$0.23-$0.79$0.67 million$1.37 million8/8/2025Q2 2025GLUCGlucose HealthN/A-$0.01N/A-$0.01N/A$0.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARTLArtelo BiosciencesN/AN/AN/AN/AN/AENSCEnsysce BiosciencesN/AN/AN/AN/AN/AGLUCGlucose HealthN/AN/AN/AN/AN/AKTTAPasithea TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARTLArtelo BiosciencesN/A0.390.39ENSCEnsysce BiosciencesN/A2.102.10GLUCGlucose HealthN/AN/AN/AKTTAPasithea TherapeuticsN/A4.974.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARTLArtelo Biosciences0.87%ENSCEnsysce Biosciences5.63%GLUCGlucose HealthN/AKTTAPasithea Therapeutics23.92%Insider OwnershipCompanyInsider OwnershipARTLArtelo Biosciences5.80%ENSCEnsysce Biosciences7.90%GLUCGlucose HealthN/AKTTAPasithea Therapeutics2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARTLArtelo Biosciences5700,000663,000Not OptionableENSCEnsysce Biosciences102.97 million2.73 millionNot OptionableGLUCGlucose Health147,00017.41 millionN/ANot OptionableKTTAPasithea Therapeutics37.44 million7.24 millionNot OptionableGLUC, ARTL, KTTA, and ENSC HeadlinesRecent News About These CompaniesPasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment ConferenceAugust 29, 2025 | globenewswire.comPasithea Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceAugust 28, 2025 | markets.businessinsider.comPasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 PatientsJuly 31, 2025 | globenewswire.comKTTA Pasithea Therapeutics Corp. - Seeking AlphaJuly 25, 2025 | seekingalpha.comPasithea Therapeutics schedules 2025 annual meeting for September 3July 13, 2025 | investing.comPasithea Therapeutics Appoints Dr. James Lee to Scientific Advisory Board to Advance PAS-004 Development for Inflammatory DiseasesJune 12, 2025 | nasdaq.comPasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory BoardJune 11, 2025 | globenewswire.comPasithea Therapeutics Reports Promising Interim Results for PAS-004 in Phase 1 Trial for Refractory Solid Tumors at ASCO 2025June 4, 2025 | nasdaq.comPasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025June 2, 2025 | globenewswire.comPasithea Therapeutics Reports Promising Preclinical Data for PAS-004 as a Novel MEK Inhibitor for Inflammatory DiseasesMay 21, 2025 | nasdaq.comPasithea Announces Strong Preclinical Results For PAS-004 In Inflammatory Disease ModelMay 21, 2025 | nasdaq.comPasithea Therapeutics Stock Draws Retail Buzz As Early Data Shows Potential In Treating Inflammatory DiseasesMay 21, 2025 | msn.comPasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market DiseasesMay 20, 2025 | globenewswire.comPasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial SiteMay 14, 2025 | globenewswire.comPasithea Therapeutics Closes $5 Million Public Offering to Advance Development of PAS-004 for Neurofibromatosis and Cancer IndicationsMay 9, 2025 | nasdaq.comPasithea Therapeutics Announces Closing of $5 Million Public OfferingMay 7, 2025 | finance.yahoo.comPasithea Therapeutics Raises $6.3 Million in Stock OfferingMay 7, 2025 | tipranks.comPasithea Therapeutics Announces Closing of $5 Million Public OfferingMay 7, 2025 | globenewswire.comPasithea Therapeutics Announces Pricing of $5 Million Public OfferingMay 6, 2025 | finance.yahoo.comPasithea Therapeutics Stock Soars After Positive Data From Cancer Drug Trial: Retail’s ElatedMay 6, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGLUC, ARTL, KTTA, and ENSC Company DescriptionsArtelo Biosciences NASDAQ:ARTL$9.25 +0.21 (+2.32%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$9.37 +0.12 (+1.30%) As of 08/29/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.Ensysce Biosciences NASDAQ:ENSC$2.09 -0.01 (-0.48%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$2.12 +0.03 (+1.63%) As of 08/29/2025 05:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.Glucose Health OTCMKTS:GLUC$0.09 +0.00 (+2.28%) As of 08/29/2025 12:35 PM EasternGlucose Health, Inc. engages in the formulation, manufacturing, marketing, and distribution of soluble fiber infused nutritional beverages. It offers soluble fiber infused powdered iced tea, and flavored drink mixes for pre-diabetic and diabetic persons under the GLUCODOWN brand in North America. The company was formerly known as Bio-Solutions Corp. and changed its name to Glucose Health, Inc. in November 2014. Glucose Health, Inc. was incorporated in 2007 and is based in Bentonville, Arkansas.Pasithea Therapeutics NASDAQ:KTTA$0.81 -0.03 (-3.91%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$0.83 +0.02 (+2.45%) As of 08/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant With Shares Near Highs, Here's to Watch in Broadcom's Q3 Report Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
